Skip to main
University-wide Navigation

Research Advancing Kentucky: Propelling the science behind cancer care

B. Mark Evers, M.D., is the director of the UK's Markey Cancer Center, physician in chief of oncology service and a professor of surgery in the UK College of Medicine. Markey is 1 of only 72 National Cancer Institute-Designated Comprehensive Cancer Centers in the country. It’s the first and only center in Kentucky to achieve this designation. 

 

 

 

Research Advancing Kentucky: Providing crucial supports for researchers

Katherine Hartmann, M.D., Ph.D., is the director of the UK Center for Clinical and Translational Science (CCTS) and a professor of obstetrics and gynecology in the UK College of Medicine. CCTS’ goal is to deliver solutions for researchers across UK’s 16 colleges and UK HealthCare. It is currently funded by a prestigious award from the National Center for Advancing Translational Sciences (NCATS). 

 

 

 

Research Advancing Kentucky: Transforming aging and brain

Linda Van Eldik, Ph.D., is the director of the UK Sanders-Brown Center on Aging and a professor of neurology in the UK College of Medicine. An integral part of Sanders-Brown is the UK Alzheimer's Disease Research Center (ADRC) — one of the original 10 centers funded by the NIH’s National Institute on Aging (NIA).  


 

 


 

Research Advancing Kentucky: Providing hope to pediatric cancer patients

John D’Orazio, M.D., Ph.D., is supported by the NIH’s National Cancer InstituteNational Institute of General Medical Sciences and National Institute of Environmental Health Sciences. D’Orazio is a professor in the Department of Pediatrics in the UK College of Medicine and holds joint faculty positions in physiology, pharmacology and nutritional sciences, and toxicology. He is also the chief of the Division of Hematology/Oncology – Pediatric at Kentucky Children’s Hospital.  

 

How NIH funding supports resources for UK researchers

The National Institutes of Health (NIH) support research at the University of Kentucky in a variety of ways — from individual grants to supports for centers and graduate students. Acting Vice President for Research Ilhem Messaoudi offers a breakdown of this support as part of a recent video campaign from Research Communications

 

 

Research Advancing Kentucky: Preserving the golden years

Greg Jicha, M.D., Ph.D., is supported by the NIH’s National Institute on Aging, which leads research on aging, the aging process and diseases and conditions associated with growing older, in order to extend the healthy, active years of life. 

 

 

 

Research advancing Kentucky: How NIH-funded discoveries drive UK’s impact

LEXINGTON, Ky. (April 28, 2025) — The University of Kentucky plays a critical role in advancing the health, well-being and future of the Commonwealth through impactful research. As Kentucky’s flagship, land-grant institution, UK focuses its resources, expertise and key partnerships to address the challenges facing our state to improve the quality of life for Kentuckians. 

UK study highlights harmful connection between obesity, kidney disease

LEXINGTON, Ky. (April 24, 2025) — A comprehensive new review by researchers at the University of Kentucky sheds light on the intricate and damaging relationship between obesity and kidney disease. The review, recently published in the prestigious Nature Reviews Nephrology, details the multiple ways in which excess fat tissue disrupts kidney function and even triggers changes in the brain that further exacerbate renal damage. Conversely, when the kidneys aren’t working properly, that can also affect adipose tissue (or body fat).

Markey reaches 10,000 patient milestone in national cancer research network

LEXINGTON, Ky. (April 22, 2025) – The University of Kentucky Markey Cancer Center has enrolled its 10,000th patient in the Oncology Research Information Exchange Network (ORIEN) since joining the alliance in 2017. ORIEN is a national consortium of 19 leading cancer centers that collaborate by sharing anonymized patient data and tissue samples through the Total Cancer Care® (TCC) protocol. This comprehensive approach follows consented patients throughout their lifetime, allowing researchers to develop more targeted treatments and anticipate changes in patients’ conditions.